Current Problems in Provision of Orphan Drugs and Ways to Solve Them
Despite the fact that orphan (rare) diseases are characterized by a very low prevalence rate, a considerable number of people worldwide suffer from these diseases. The United States and the European Union developed a variety of economic and administrative incentives for pharmaceutical companies to p...
Saved in:
| Main Authors: | Alexei S. Kolbin, Roman A. Gapeshin, Stanislav M. Malyshev |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2016-09-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/1651 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01) -
EMA approved orphan medicines since the implementation of the orphan legislation
by: Eveliina Hahl, et al.
Published: (2025-06-01) -
Visual Research of Global Orphan Drug from a Bibliometric Perspective
by: Wen X, et al.
Published: (2025-05-01) -
Features of intellectual property protection mechanisms on the example of orphan drugs circulation
by: D. S. Yurochkin, et al.
Published: (2022-01-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)